Eupraxia Pharmaceuticals Inc. balance sheet

At the end of fiscal 2025, Eupraxia Pharmaceuticals Inc. had total assets of $86.2m, total liabilities of $5.7m and shareholders' equity of $82.0m. It held $80.6m in cash against $0 of debt: net cash of $80.6m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Eupraxia Pharmaceuticals Inc.: balance sheet, annual
Fiscal year	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash and equivalents	19	33	81
Receivables	0	0	1
Total current assets	20	34	85
Total assets	20	35	86
Accounts payable	1	0	1
Total current liabilities	19	3	6
Total debt	—	0	0
Total liabilities	19	3	6
Shareholders' equity	2	33	82
Non-controlling interests and other (assets − liabilities − equity)	−1	−2	—
Net debt (negative = net cash)	−19	−33	−81
Shares outstanding	27m	36m	—

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Eupraxia Pharmaceuticals Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Eupraxia Pharmaceuticals Inc.